MedTrace Logo

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

NCT01489423 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of tissue and blood in the laboratory from patients treated with ipilimumab with or without sargramostim may help doctors learn more about the effects of ipilimumab and sargramostim on cells. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research trial studies tissue and blood biomarkers in patients with stage III melanoma or stage IV melanoma treated with ipilimumab with or without sargramostim.

Conditions

  • Melanoma (Skin)

Interventions

GENETIC

RNA analysis

GENETIC

in situ hybridization

GENETIC

polymerase chain reaction

OTHER

enzyme-linked immunosorbent assay

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • F. Stephen Hodi, MD · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-26
Primary Completion
2013-05-26
Completion
2013-05-26

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01489423 on ClinicalTrials.gov